Advertisement
Advertisement
U.S. Markets open in 4 hrs 11 mins
Advertisement
Advertisement
Advertisement
Advertisement

Skye Bioscience, Inc. (SKYE)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0467-0.0001 (-0.21%)
At close: 03:51PM EST
Advertisement

Skye Bioscience, Inc.

5910 Pacific Center Boulevard
Suite 320
San Diego, CA 92121
United States
949 480 9051
https://skyebioscience.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Punit S. Dhillon B.A., BACEO, Pres, Principal Accounting Officer, Sec. & Exec. Chairman228.08kN/A1980
Ms. Kaitlyn Melanie Arsenault CPAChief Financial OfficerN/AN/AN/A
Mr. Karam TakharVP of Corp. Devel. & Investor RelationsN/AN/AN/A
Mr. Tom Kim Esq.Gen. Counsel & Director of IPN/AN/AN/A
Mr. Tu Diep M.Sc.Chief Devel. OfficerN/AN/AN/A
Ms. Rhea Williams M.P.H.Head of Regulatory Affairs & Quality AssuranceN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based therapeutics for the treatment of infectious diseases. The company's lead product candidate is THCVHS, which is in preclinical trials for the treatment of glaucoma. It is also developing CBDVHS that is in preclinical trials to treat various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and Cannabinoid Cocktail for the treatment of anti-infective diseases. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.

Corporate Governance

Skye Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement